Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 1

531 - Prognostic prediction models for patients with stage IV colorectal cancer after concurrent curative resection


19 Dec 2015


Poster presentation 1


Norikatsu Miyoshi


Annals of Oncology (2015) 26 (suppl_9): 42-70. 10.1093/annonc/mdv523


N. Miyoshi, M. Ohue, M. Yasui, K. Sugumira, A. Tomokuni, H. Akita, K. Demura, S. Kobayashi, H. Takahashi, T. Omori, Y. Fujiwara, M. Yano

Author affiliations

  • Surgery, Osaka Medical Center for Cancer and Cardiovascular Dideases, 5378511 - Osaka/JP


Abstract 531


We developed a prediction tool for recurrence and survival in patients with stage IV colorectal cancer (CRC) following surgically curative resection.


From January 1983 to December 2010, 97 patients with CRC and synchronous liver and/or lung metastatic CRC were investigated at the Osaka Medical Center for Cancer and Cardiovascular Diseases. All patients underwent curative resection of both primary and metastatic lesions. A Cox proportional hazards model was used to develop prediction models for 3-year relapse-free survival (RFS) and cancer-specific survival (CSS).


Univariate analysis of clinicopathological factors showed that the following factors were significantly correlated with RFS and CSS: preoperative serum carcinoembryonic antigen level, tumor location, pathologically defined tumor invasion, and synchronous metastatic lesions. Using these variables, novel prediction models predicting RFS and CSS were constructed using the logistic regression model with AUC of 0.787 and 0.853 for RFS and CSS, respectively. The prediction models were validated by external datasets in an independent patient group.


We developed novel and reliable personalized prognostic models, integrating not only TNM factors but also the preoperative serum carcinoembryonic antigen level, tumor location, and metastatic lesions, to predict patients' prognosis following surgically curative resection. These individualized prediction models may help clinicians in the treatment of postoperative stage IV CRC following surgically curative resection.

Clinical trial identification


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings